Article Figures & Data
Figures
- Figure 1.
LIN28B overexpression in colon carcinomas correlates with reduced survival and increased probability of tumor recurrence. A–D, representative H&E and IHC for LIN28B in matched normal mucosa and colon carcinomas in tissue microarrays. LIN28B staining is intense in a subset of colon tumors. Magnification: 100× in A–D. E, LIN28B expression and patient survival. High LIN28B staining intensity in stage I and II colon cancers correlates with reduced patient survival. F, LIN28B and tumor recurrence. High LIN28B staining intensity in stage I and II tumors correlates with increased probability of tumor recurrence.
- Figure 2.
LIN28B tumors have reduced size. A, LIN28B tumors emit less fluorescence than controls. GFP intensity of xenograft tumors was assessed at biweekly intervals; at each interval, fluorescence intensity for LIN28B tumors was less than that of controls. Representative 2- and 4-week analyses of a single cohort injected with vector-LoVo or LIN28B-LoVo cells. B, LIN28B tumors are smaller than controls. Tumor weights 6 weeks postinjection and extraction.
- Figure 3.
Histopathologic examination of empty vector and LIN28B-expressing primary tumors. A and B, confirmation of LIN28B overexpression in tumors. Immunohistochemical detection of LIN28B in vector-LoVo and LIN28B-LoVo xenografts; representative of 83 tumors tested (200× magnification). C–F, H&E staining of xenograft tumors. Empty vector tumors, which exhibit broad areas of necrosis (C) and poor differentiation (E), whereas LIN28B-expressing tumors exhibit fewer necrotic areas (D), moderate differentiation, glandular formation, and increased mucin production (F). Magnification: 100× in C and D; 200× in E and F.
- Figure 4.
Differentiation and mucin production in LIN28B tumors. A, poor differentiation in xenograft tumors. Area exhibiting poor differentiation scored as a percentage of viable tumors. LIN28B-expressing tumors exhibit fewer areas of poor differentiation. B, moderate differentiation in xenograft tumors. Area exhibiting moderate differentiation scored as a percentage of viable tumors. Moderate differentiation is increased in LIN28B-expressing tumors. C, mucin positivity in poorly differentiated tumor areas. Mucin was detected via mucicarmine staining. Mucin positivity in poorly differentiated area scored as a percentage of viable tumor. D, mucin positivity in moderately differentiated tumor areas. Mucin positivity in poorly differentiated area scored as a percentage of viable tumor. Differentiation is increased in LIN28B-expressing tumors. Mucin production is increased in LIN28B-expressing tumors.
- Figure 5.
A subset of LIN28B-expressing primary tumors metastasize. A, lung metastasis from a LIN28B-DLD-1 subcutaneous tumor. H&E staining. B, liver metastasis from a LIN28B-LoVo subcutaneous tumor. H&E staining; note invasion of metastasis into normal liver (C and D) metastases are GFP-positive. IHC for GFP expressed from MSCV-PIG retroviral vector confirms that these tissues originated from xenograft injections. E, metastases visible upon gross examination. Arrows indicate liver and mesenteric metastases from LIN28B-LoVo tumors. Magnification: 100× in A and B; 200× in C and D.
Tables
- Table 1.
Transcripts upregulated by LIN28B
Gene symbol Gene name Fold changeb (vector vs. LIN28B) Transcripts upregulated by constitutive LIN28B expression in vitroa LGR5 Leucine-rich repeat-containing G-protein–coupled receptor 5 7.2 PROM1 Prominin 1 22.6 KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 36.6 HMGA2 High mobility group AT-hook 2 2.6 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 9.4 CCND2 Cyclin D2 6.6 DKK1 Dickkopf homolog 1 37.1 Fold changeb (tumor vs. metastases) Transcripts upregulated in LIN28B-expressing metastases in vivoc CHI3L1 Chitinase 3-like 1 4.4 KLK6 Kallikrein-related peptidase 6 4.3 TNS4 Tensin 4 4.6
Supplementary Data, King, et al.
Files in this Data Supplement:
Volume 71, Issue 12
